3月 2026
- 首頁
- RECORDATI
3月 2026RECORDATI的市場佔有率分析
Who we are Recordati has been at the forefront of life-enhancing and life-changing medicines for 100 years. With its beginnings in a family run pharmacy in Correggio, Italy in the 1920s, Recordati is now a global pharmaceutical force, listed on the Italian stock exchange, with around 4,580 employees. Learn More Who we are Recordati… Continue reading Company – Who we are
RECORDATI(包含公司地區)
查看更多網站流量與參與度資訊- recordati.com
RECORDATI截至 3月 2026 的總收入為 > 1B
RECORDATI 熱門網域產生的總收入
RECORDATI 熱門網域 3 年內的總收入
RECORDATI 熱門網域的總收入
3月 2026RECORDATI的股票價格
RECORDATI 股票交易代碼 #REC。以下是截至 3月 2026RECORDATI 過去 12 個月的股票績效
RECORDATI的熱門網域總造訪量
了解RECORDATI市場觸達率與潛在市場影響力。
過去 3 個月的訪問總量
子公司細目
RECORDATI的熱門網域平均造訪時長
分析RECORDATI參與度指標。
過去 3 個月平均造訪時長
子公司細目
RECORDATI的熱門網域平均頁面瀏覽量
了解RECORDATI如何保持使用者的參與度、培養其興趣,並鼓勵他們採取下一步。
過去 3 個月平均頁面瀏覽量
子公司細目
想要取得更深入的流量洞見?
篩選超過 2,030 萬家線上企業。在流量激增、開始或停止使用技術或獲得正面評價時,發現新的潛在客戶。
新聞與訊號來自RECORDATI
透過 Similarweb 銷售訊號提醒,每當目標受眾出現新的機會或威脅時,你就會收到每日更新的已識別購買訊號。
新聞Recordati Group is developing mRNA-3927 for propionic acidemia.Moderna is collaborating with Recordati to develop its mRNA-3927 for propionic acidemia, a rare metabolic disorder with a lack of available disease modifying treatment.
1月 30, 2026閱讀更多
新聞Recordati Group partnered with Moderna Therapeutics Inc. on Jan 30th '26.Milan, 29 January 2026 - Recordati today announced that it has entered into a collaboration and license agreement with Moderna to develop and commercialize worldwide mRNA-3927, an investigational product for the treatment of propionic acidemia (PA).
1月 29, 2026閱讀更多
新聞Recordati Group hires Mike mcclellan as Chief Financial Officer.Recordati appoints Mike mcclellan as new Chief Financial Officer.
10月 23, 2025閱讀更多
查看所有RECORDATI信號
讓銷售團隊專注於最有希望的機會。透過安排機會的優先順序,並在正確的時間參與,您可將工作最佳化,並完成更多交易。
